Core Viewpoint - The company has entered into a strategic partnership and non-exclusive technology licensing agreement with EirGenix, a global biopharmaceutical development and manufacturing enterprise, to utilize its HiCB platform for enhanced biopharmaceutical production efficiency [1][2] Group 1: Partnership and Agreement Details - The agreement grants EirGenix a non-exclusive license to the HiCB platform, which includes high-yield continuous perfusion upstream processes and integrated mixed continuous downstream purification technology [1] - The company will receive a significant upfront payment and milestone payments, along with future royalties from the commercialization of the licensed technology [1] Group 2: Technology and Benefits - The HiCB platform aims to achieve higher process efficiency, optimize process control, and ensure product consistency, significantly reducing production costs compared to traditional fed-batch production methods [1] - This collaboration is expected to enhance the affordability and accessibility of high-quality biopharmaceuticals for patients globally [2] Group 3: Future Implications - The revenue generated from this and future collaborations will be reinvested into strengthening the technology platform and advancing the research and development pipeline for next-generation innovative therapies [2]
创胜集团-B(06628)与台康生技达成战略合作与非独占技术许可协议